arrow
R

Roland B. Walter

Fred Hutchinson Cancer Center
H指数:69
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms

CPX-351与CLAG-M(克拉屈滨、环胞苷、G-CSF和米托蒽醌)治疗不适合常规治疗的急性髓系白血病或其他高级别髓系肿瘤成年患者的随机Ⅱ期临床试验

Leukemia
IF13.4
2026-07-130
PRE
Defining the Limits of Pre-Transplant Risk Prediction in AML: Evidence from Machine Learning and Regression Models.

定义AML移植前风险预测的界限:机器学习与回归模型的证据。

2025-12-310
OAAI
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party

2025年急性髓系白血病微小残留病更新:ELN-DAVID微小残留病工作组共识文件

Blood
IF23.1
2025-12-160
OAAI
Distal gut colonization by oral bacteria during intensive chemotherapy: direct evidence from strain-level analysis of paired samples

在强化化疗期间口腔细菌对远端肠道的定植:来自配对样本菌株水平分析的直接证据

2025-05-260
OA
TNFα Apoptotic Signaling By Antigen-Engaged CAR T-Cells Mediates Clearance of Target Antigen-Negative Acute Myeloid Leukemia

TNFα介导的抗原激活CAR T细胞凋亡信号清除靶抗原阴性的急性髓系白血病

BLOOD
IF23.1
2024-11-050
PRE
Phase I Trial Combining Venetoclax with Cladribine, Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) for Patients with Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms

I期临床试验:将Venetoclax与克拉屈滨、环胞苷、G-CSF和米托蒽醌(CLAG-M)联合用于急性髓系白血病(AML)和高级别髓系肿瘤患者

BLOOD
IF23.1
2024-11-050
PRE
A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

一项I期研究,旨在评估吉姆单抗奥佐米星和米哚妥林在联合标准剂量阿糖胞苷和柔红霉素诱导治疗新诊断FLT3突变急性髓性白血病时的安全性与耐受性。

BLOOD
IF23.1
2024-11-050
PRE